Piramal Pharma Limited has informed the Exchange regarding 'Business Responsibility & Sustainability Report for the financial year 2024-25
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Piramal Pharma has submitted its mandatory Business Responsibility & Sustainability Report (BRSR) for FY 2024-25 to the stock exchanges, as required under SEBI Listing Regulations. The company is a pure-play pharmaceutical manufacturer with 18 global plants and exports contributing 68.55% of its ₹5,285.71 Crore turnover. It employs 5,216 permanent staff and 3,346 workers, with 30% female representation on the board. PPL has set science-based targets to cut Scope 1 & 2 emissions by 42% by FY 2030 and Scope 3 emissions by 25%, and has achieved zero hazardous waste to landfill. During FY25, the company paid around ₹25.85 Crore in regulatory penalties, fines, and a VetDC settlement, though no bribery or corruption cases were reported.
This is a routine regulatory ESG disclosure and is unlikely to move the stock on its own, but investors can track PPL's decarbonisation targets, diversity metrics, and the cumulative regulatory penalties (~₹25.85 Cr) which have been contested in part. The report highlights rising concentration of sales via dealers (97%) and a significant increase in payables cycle to 182 days from 140 days.